Cerebral Spinal Fluid Management Market size is likely to gain notable traction during the forecast timeline of 2023-2032.
One of the key factors favoring the market outlook is the growing adoption of tests to analyze a patient’s cerebrospinal fluid (CSF) level to diagnose underlying conditions, such as meningitis and other infectious ailments associated with the brain and spinal cord. The prevalence of chronic rhinosinusitis with nasal polyps is increasing in many countries.
This will stimulate the usage of cerebrospinal fluid (CSF) management devices over the coming years. These instruments are also used to manage the raised intracranial pressure by safely removing the cerebrospinal fluid from ventricles of the lumbar spine or brain.
Chronic health conditions, such as congenital hydrocephalus are rising among infants. According to data by Johns Hopkins Medicine, one or two of every 1,000 infants born in the U.S. are affected by this condition. Likewise, the incidence of brain tumors is increasing in countries including the U.K. as the growth of these tumors is often linked with the leakage of CSF through the brain covering. According to the U.K. NHS, over 11,000 individuals are diagnosed with a primary brain tumor across the country every year, further generating growth opportunities for the industry in the future.
In terms of patient type, global cerebral spinal fluid management market is segmented into pediatric, adult, and geriatric. The industry revenue from the geriatric patient segment is set to record commendable growth by 2032. Elderly people are at a higher risk of contracting autoimmune disorders due to their susceptibility to antinuclear antibodies.
Based on end-use, cerebral spinal fluid management market is divided into ambulatory surgical centers, clinics, hospitals, and neurological centers. Neurological centers are expected to account for a large market share by 2032. The occurrence of brain disorders has risen considerably in recent years due to various factors, such as family history, old age, chronic stress, and unhealthy lifestyle habits. The number of U.S. citizens being diagnosed with Alzheimer’s disease and related dementias is anticipated to grow to 9.3 million by 2060.
This has prompted medical institutions to expand the network of neurological centers to keep up with the rising number of patients suffering from neurological disorders. For example, in April 2022, U.S.-based Barrow Neurological Institute opened a new neuroscience facility to enhance medical care for patients undergoing treatment for various neurological conditions. Such initiatives will amplify the industry progress.
Asia Pacific CSF management market is estimated to register a notable CAGR during the analysis timeline as the region has a vast presence of highly skilled neurosurgeons. The percentage of the region’s elderly population is also expanding steadily every year. The WHO predicts that the population of people in China aged 60 years and above will touch 28% by 2040 due to declining fertility rate and longer life expectancy. These factors, along with the high occurrence of Japanese encephalitis in the country, will accelerate the regional industry growth.
Companies, such as Sophysa, Spiegelberg, Integra LifeSciences, Medtronic, DePuy Synthes Companies (Johnson & Johnson), Dispomedica (Neuromedex GmbH), B. Braun Melsungen, and BeckerSmith Medical, among several others, are the key participants of cerebral spinal fluid management market. These firms are focusing on business expansions, acquisitions, new service launches, and mergers to strengthen their global footprint.